fasedienol   Click here for help

GtoPdb Ligand ID: 14431

Synonyms: 4-androstadienol | [3β]-androsta-4,16-dien-3-ol | aloradine | PH-94B | PH94B
Compound class: Synthetic organic
Comment: Fasedienol (PH94B; VistaGen Therapeutics, formerly Pherin Pharmaceuticals) is a pherine, or vomeropherin [4]. Pherines are synthetic neuroactive steroids that are intended to acts as human pheromones via interactions with receptors on nasal chemosensory neurons within the vomeronasal organ (VNO). They are proposed to alter central nervous system activity (e.g., within the limbic amygdala and hypothalamus) through the olfactory system, and without crossing the blood-brain barrier, in turn inducing physiological, pharmacological and behavioural changes. Fasedienol is claimed to be pharmacologically active, achieving rapid-onset and short-duration anxiolytic effects, without systemic distribution or direct activity on neurons in the brain. Note that whilst intranasal administration of fasedienol in human subjects is reported to elicit biological and physiological responses [2-3], the functional capacity of vomeronasal receptors and the VNO in humans is open to debate [1,5-7].
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 1
Hydrogen bond donors 1
Rotatable bonds 0
Topological polar surface area 20.23
Molecular weight 272.43
XLogP 5.7
No. Lipinski's rules broken 1

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C[C@]12C=CC[C@H]2[C@@H]3CCC4=C[C@H](CC[C@]4(C)[C@H]3CC1)O
Isomeric SMILES C[C@]12CC[C@H]3[C@H]([C@@H]1CC=C2)CCC4=C[C@H](CC[C@]34C)O
InChI InChI=1S/C19H28O/c1-18-9-3-4-16(18)15-6-5-13-12-14(20)7-11-19(13,2)17(15)8-10-18/h3,9,12,14-17,20H,4-8,10-11H2,1-2H3/t14-,15-,16-,17-,18-,19-/m0/s1
InChI Key NYVFCEPOUVGTNP-DYKIIFRCSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
Fasedienol (PH94B) was progressed as a clinical candidate, proposed to alleviate social anxiety disorder.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT06809179 A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder Phase 2 Interventional VistaGen Therapeutics, Inc.
NCT02622958 Feasibility Study of PH94B Nasal Spray for Acute Treatment of Social Anxiety Disorder (SAD) Phase 3 Interventional Pherin Pharmaceuticals, Inc. 2
NCT06358651 Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3) Phase 3 Interventional VistaGen Therapeutics, Inc. The PALISADE-3 study: In December 2025 Vistagen reported that intranasal fasedienol provided no statistically better effect than placebo (measured as improvement in a self-reported distress assessment) in participants with social anxiety disorder (SAD).
NCT06615557 Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4) Phase 3 Interventional VistaGen Therapeutics, Inc. The PALISADE-4 study: In June 2026 it was reported that compared to placebo, fasedienol did not reduce anxiety symptoms in subjects who participated in a simulated anxiety-inducing public speaking challenge [...]. A marginally statistically significant beneficial effect was noted when analysing the Subjective Units of Distress Scale (SUDS) as the primary endpoint in a subpopulation of patients with pre-existing very severe social anxiety, (n=123, out of a total of 238 trial recruitees).